A clinical trial to investigate FLX-475 alone and in combination with an immune checkpoint inhibitor in patients with cancer

Trial Profile

A clinical trial to investigate FLX-475 alone and in combination with an immune checkpoint inhibitor in patients with cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs FLX-475 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Dec 2017 New trial record
    • 21 Dec 2017 According to an FLX Bio media release, this trial is expected to begin in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top